Ho Yeong Lim

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · New England Journal of Medicine · 2020 · 7.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

Brian I. Rini, Bernard Escudier, Piotr Tomczak et al. · The Lancet · 2011 · 1.8K citations

Medicine, Oncology, Pharmacology +8

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle et al. · Journal of Clinical Oncology · 2019 · 1.8K citations

Pharmacy, Oncology, Pharmacotherapy +13

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Seung Tae Kim, Răzvan Cristescu, Adam J. Bass et al. · Nature Medicine · 2018 · 1.7K citations

Medicine, Cancer Biology, Oncology +17

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen et al. · The Lancet Oncology · 2019 · 1.7K citations

Medicine, Oncology, Pharmacology +13